5 Top Losers Of The Day: ECOR, GRTS, AVRO...

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. electroCore Inc. (ECOR)

electroCore is a commercial-stage bioelectronic medicine company.

Lost 19.19% to close Tuesday's (Jan.8) trading at $5.89.

News: No news

The Company's marketed product is GammaCore, which was given clearance in the U.S. for the acute treatment of pain associated with episodic cluster headache in April 2017, for acute treatment of pain associated with migraine headache in adult patients in January 2018, and for adjunctive use for the preventive treatment of cluster headache in adult patients in November 2018.

GammaCore is a non-invasive vagus nerve stimulator (nVNS) therapy.

PREMIUM II, a multicenter, prospective, double-blind, randomized, sham-controlled study of GammaCore for the preventive treatment of migraine in the U.S. has been initiated. This study is designed to enroll up to 500 patients in 35 sites in the United States, with an anticipated duration of 18 months.

2. AVROBIO Inc. (AVRO)

Lost 17.36% to close Tuesday's trading at $13.04.

News: No news

Near-term Catalysts:

-- Further updates on the investigator-sponsored phase I study, and the AVROBIO-sponsored phase II clinical trial of gene therapy AVR-RD-01 in Fabry disease are expected in the first quarter of 2019. -- An investigator-sponsored phase I/II study of AVR-RD-04, a gene therapy candidate, being investigated for the treatment of patients with cystinosis, by the University of California, San Diego, remains on track to enroll the first patient in 2019.

3. Viveve Medical Inc. (VIVE)

Viveve Medical is a medical technology company focused on women's intimate health.

Lost 12.72% to close Tuesday's trading at $0.96.

News: No news

Clinical Trials & Near-term Catalysts:

-- A clinical trial to assess the safety and effectiveness of Viveve System for the improvement of sexual function in women following vaginal childbirth, dubbed VIVEVE II Study, is underway. This study is designed to enroll roughly 250 subjects at up to 25 study sites in the United States and Canada. -- A multi-center study evaluating its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women, dubbed LIBERATE-International, is ongoing.

4. Natera Inc. (NTRA)

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA.

Lost 11.16% to close Tuesday's trading at $11.46.

News: No news

Clinical Trials & Near-term Catalysts:

-- A study evaluating the clinical utility of Panorama, a non-invasive prenatal test to screen for aneuploidies and microdeletion genetic conditions, such as 22q11.2 deletion syndrome (DiGeorge syndrome), dubbed SMART, is underway. This study has enrolled 20,000 patients, and primary study results are expected in 2019. -- The Company is slated to report fourth quarter and fiscal year 2018 financial results in March.

Natera anticipates 2018 total revenue to be in the range of $250 million to $260 million. The consensus revenue estimate of analysts polled by Thomson Reuters is $256.57 million. The total revenue in 2017 was $210.9 million.

5. Gritstone Oncology Inc. (GRTS)

Lost 11.09% to close Tuesday's trading at $16.44.

News: No news

Recent event:

-- On September 28, 2018, the Company went public on the Nasdaq Global Select Market, offering its shares at a price of $15 each.

Pipeline & Near-term Catalyst:

The Company's lead drug candidate is GRANITE-001. The phase I portion of phase I/II study evaluating the combination of GRANITE-001 with Bristol Myers' systemic Opdivo, and a localized subcutaneous injection of Yervoy, in patients with solid tumors, dubbed GO-004, has been initiated.

Preliminary efficacy data from the phase I portion of GO-004 in patients with metastatic lung, gastric, colorectal and bladder cancers are expected to be reported in the second-half of 2019.

-- An IND application for the initiation of a first-in-human study with SLATE-001, an immunotherapy candidate using shared neoantigens for an "off-the-shelf" therapy, is planned for submission in mid-2019.